Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD.
K
K
Jackson
C
C
Curley
J
J
Leach
A
A
McLean
M
M
Nakagaki
S
S
Durrant
G A
GA
Kennedy
D000208:Acute Disease; D000074323:Alemtuzumab; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016208:Databases, Factual; D018572:Disease-Free Survival; D004351:Drug Resistance / Q000187:drug effects*; D000068800:Etanercept; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate
D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000961:Antilymphocyte Serum; D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000074323:Alemtuzumab; D000068800:Etanercept; D008775:Methylprednisolone